Jump Financial LLC Increases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Jump Financial LLC grew its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 174.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 139,280 shares of the company's stock after acquiring an additional 88,448 shares during the quarter. Jump Financial LLC owned approximately 0.16% of CRISPR Therapeutics worth $5,482,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Magnetar Financial LLC bought a new position in CRISPR Therapeutics in the 4th quarter worth approximately $359,000. Capital Market Strategies LLC bought a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at about $461,000. Vanguard Group Inc. grew its position in CRISPR Therapeutics by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock valued at $68,329,000 after buying an additional 10,579 shares in the last quarter. KBC Group NV increased its stake in shares of CRISPR Therapeutics by 2,047.4% during the fourth quarter. KBC Group NV now owns 60,514 shares of the company's stock valued at $2,382,000 after acquiring an additional 57,696 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in CRISPR Therapeutics in the fourth quarter worth approximately $3,231,000. 69.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Trading Up 3.2 %

NASDAQ:CRSP traded up $1.20 on Tuesday, hitting $39.02. The company had a trading volume of 616,435 shares, compared to its average volume of 1,627,570. The firm has a 50 day moving average of $40.82 and a two-hundred day moving average of $43.68. The stock has a market capitalization of $3.35 billion, a price-to-earnings ratio of -8.95 and a beta of 1.85. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CRSP. JMP Securities reaffirmed a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Citigroup reduced their price objective on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a research note on Tuesday, February 18th. Bank of America dropped their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Royal Bank of Canada cut their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a report on Wednesday, February 12th. Finally, Evercore ISI upgraded shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and lifted their price objective for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $73.11.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 18,360 shares of the company's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Julianne Bruno sold 1,198 shares of the business's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the sale, the chief operating officer now directly owns 8,263 shares of the company's stock, valued at $350,516.46. The trade was a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,381 shares of company stock worth $1,608,243. Company insiders own 4.10% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.